Health TrialsbyHealthPanel

Ovarian Cancer Screening and AI

ConditionOvarian Cancer Screening Recommendations by Gynecologists
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age24+
SponsorCharite University, Berlin, Germany

About this trial

Gynecologists frequently overestimate the benefits and safety of ovarian cancer screening. AI-supported discussions may help correct these misperceptions. This study tests whether an AI-guided conversation about the evidence on ovarian cancer screening can improve gynecologists' knowledge and reduce non-evidence-based screening recommendations, compared with a control AI discussion on ovarian cancer prevalence.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

gynecologists in outpatient care who provide ovarian cancer screening to asymptomatic, average-risk women (not guideline consistent)

Disqualifiers

gynecologists in inpatient care

gynecologist in outpatient care who do NOT provide ovarian cancer screening to asymptomatic, average-risk women (guideline consistent)

Trial design

Design model

Parallel

Treatments tested in this trial

  • ChatGPT - Control

    Behavioral

    Three-turn conversation; discusses ovarian cancer risk and epidemiology; avoids screening topics; concise responses (5-8 sentences). Mode of Delivery: Online chat interface; participant interacts directly with ChatGPT.

  • ChatGPT - Evidence-Based Screening Discussion

    Behavioral

    Three-turn conversation; asks participants about screening rationale; provides evidence-based info on benefits/harms, trial data, guideline positions; concise responses (5-8 sentences). Mode of Delivery: Online chat interface; participant interacts directly with ChatGPT.

Treatment groups

350 Participants
are divided into 2 treatment groups
Group A: Control (ChatGPT Control Condition)Other 1 intervention
Group B: Experimental (ChatGPT Evidence-Based Screening Discussion)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in intention to recommend ovarian cancer screening

Difference in participants' self-reported frequency of recommending ovarian cancer screening to average-risk women in the future after the ChatGPT interaction and their self-reported frequency of recommending the screening in the past.

Time frame
Immediately post intervention

Secondary outcomes

1

Change in benefit-harm ratio evaluation of ovarian cancer screenings

Difference between the self-reported benefit-harm ratio evaluation before and after the ChatGPT interaction.

Time frame
Immediately post intervention
2

Accuracy of knowledge regarding ovarian cancer screening evidence

Participants' understanding of benefits, harms, and guideline recommendations for ovarian cancer screening, assessed via survey questions

Time frame
Immediately post intervention

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Charite University, Berlin, Germany

Lead sponsor

Max Planck Institute for Human Development

Collaborator

German Research Foundation

Collaborator

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: